Seeking to develop new bispecific immunotherapies, Genmab has gained exclusive access to multiple proprietary targets from Immatics Biotechnologies (Immatics), identified by the latter’s Xpresident® and T cell receptor technology. The collaboration will combine both companies’ technology and expertise in a deal worth up to US$1.7 B as well as tiered royalties on sales. For Genmab, this agreement follows the termination of a licensing deal with Janssen after a trial with Darzalex (daratumumab) in combination with Roche’s Tecentriq (atezolizumab) in patients with advanced or metastatic non-small cell lung cancer was stopped.